Collaboration brings together two leaders in ambulatory ECG recording and analysis SANTA CLARA, Calif. & NEW YORK / Apr 24, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology, bringing together two innovation...Read more
Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response PALO ALTO, Calif. / Apr 24, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s...Read more
HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the world's first interpretable cell simulation platform. This partnership is set to revolutionize biopharma drug discovery workflows by integrating Champions' state-of-the-art multi-omic dataset with Turbine's cutting-edge virtual lab...Read more
SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”)....Read more
Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics. Under the...Read more
DENVER / Apr 23, 2025 / Business Wire / Illinoisans now have easy access to user friendly enhanced health stations through a collaboration between Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a healthcare services company integrating technology into personalized care experiences, focused on improving health outcomes, and Aetna Better Health® of Illinois, a CVS Health® company. The Modivcare Higi Stations offer self-service...Read more
MINNEAPOLIS, April 23, 2025 (GLOBE NEWSWIRE) -- OneMedNet, a leader in AI-powered Real-World Data, has announced a strategic partnership with Protege, the AI training data platform, to enable real-time access, multimodal patient data for AI developers and researchers. Through this collaboration, OneMedNet’s data will be made available via Protege, expanding access to high-quality datasets for building next-generation AI solutions in...Read more
CHICAGO / Apr 23, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover...Read more
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore’s public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore...Read more
Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of...Read more
Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR’579) /IPH6101 currently in development for AML Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions Sanofi to continue development of BCMA targeting ANKET® program in autoimmune indications Innate still eligible for more than €1 billion R&D and commercial milestones MARSEILLE, France / Apr 23,...Read more
CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI’s ongoing commitment to...Read more
Machine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment BALTIMORE / Apr 22, 2025 / Business Wire / TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to...Read more
MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), a global initiative to prevent Alzheimer’s disease and improve brain health, today announced that PacBio (NASDAQ: PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be a technology partner to its North African Dementia Registry (NADR) project. Spearheaded by DAC, this effort brings...Read more
BOSTON, April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be...Read more
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- iBio (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio’s patented Machine-Learning Antibody Engine. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss...Read more
Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need TORONTO / Apr 21, 2025 / Business Wire / Cybin Inc. (NYSE...Read more
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative new treatment to accelerate chronic wound healing. A multi-year exclusive agreement between PAM Health and Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company at the forefront of biodynamic therapies, means Nuo’s Aurix System will serve...Read more
Galmed Pharmaceuticals (Nasdaq: GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these...Read more
Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1...Read more
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests...Read more
FREMONT, Calif. / Apr 15, 2025 / Business Wire / Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5)...Read more
ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of...Read more
FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of SpecialtyHealth, Inc. (“SpecialtyHealth”) — co-founded by Dr. EJ Greenwald, the pioneer of the “Famous Police Panel” — as a strategic partner. SpecialtyHealth will be integrated into...Read more
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. The candidate compound has the potential to reach patients with autoimmune diseases...Read more
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation...Read more
This strategic research collaboration – known as a Care Innovation Hub – will bring together clinicians and researchers from Cincinnati Children’s with clinical scientists and engineers from GE HealthCare to work together on projects that aim to develop the next generation of pediatric medical imaging in MR, CT, molecular imaging, ultrasound, and more. Research developed as part of the collaboration will aim to improve the consistency of...Read more
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners...Read more
CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona's proprietary H2L2 Harbour Mice® platform to identify next-generation...Read more
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition”), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations...Read more
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, heart and islet cell programs to utilize TNX-1500 for preclinical studies in support of regulatory filings for potential use in human recipients CHATHAM, N.J. and MIAMI, April 09, 2025 (GLOBE NEWSWIRE) -- Tonix...Read more
Up to $24 million in upfront and milestone payments, plus royalties Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity Kaken brings regional expertise and proven track record in commercializing innovative therapies CAMBRIDGE, Mass. & SALISBURY, England / Apr 08, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its...Read more
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce a collaboration with the Canadian Nuclear Laboratories ("CNL"). CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining...Read more
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md. and BOSTON and ROLLE, Switzerland, April 8, 2025 /PRNewswire/ -- Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its...Read more
Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into...Read more
Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales RICHMOND, Calif. / Apr 03, 2025 / Business Wire / Sangamo...Read more
TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a global agreement with Worldwide Clinical Trials ("Worldwide"), a full-service, global contract research organization (CRO)....Read more
NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor...Read more
MINNEAPOLIS, April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX...Read more
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an...Read more
FREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge Series.” This new...Read more
Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today...Read more
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize...Read more
GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr....Read more
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded...Read more
Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. CARLSBAD, Calif. / Mar 26, 2025 / Business Wire / Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries...Read more
TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief...Read more
VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer...Read more
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually) Topline efficacy and safety Phase 2 data expected to be reported at the American Urological Association meeting (AUA), being held April 26-29, 2025 in Las Vegas NDV-01 has the...Read more
RAHWAY, N.J. / Mar 25, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor...Read more
Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales Deal underscores the commercial potential of Alumis’ ESK-001 and leverages Kaken’s regional capabilities and expertise in novel dermatology treatments Kaken has the option to license ESK-001 for further clinical development...Read more
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical...Read more
New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration WALTHAM, Mass. / Mar 20, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded...Read more
Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development...Read more
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives. The first objective is to study...Read more
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB:...Read more
In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the signing of a Non-Disclosure Agreement (NDA) with the Board of Regents of the University System of Georgia by and on behalf of...Read more
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancer Black Diamond will receive an upfront payment of $70 million and up to $710 million in development and...Read more
Building on its 125-year legacy of medical imaging innovation and a 16-year relationship with NVIDIA, the two companies team up to advance AI-driven autonomous solutions designed to ease the growing burden on healthcare professionals. SAN JOSE, Calif. / Mar 18, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to...Read more
TAMPA, Fla., March 18, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a technology platform company and a disruptor in the $22 billion Third-Party Administrator ("TPA") market, is taking decisive action to revolutionize self-funded employer health plans. Today, Marpai announces a strategic collaboration with Empara, a healthcare technology innovator, and an immediate rollout of Empara's cutting-edge...Read more
SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers. To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen...Read more
Agreement brings continued access to high-quality care for Alignment’s Medicare Advantage members ORANGE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Sutter Health and Alignment Healthcare, Inc. (NASDAQ: ALHC) have renewed their agreement that provides Alignment Healthcare members with continued in-network access to Sutter’s integrated network of high-quality, comprehensive care in Northern California. This agreement applies to...Read more
BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of...Read more
Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn. / Mar 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration...Read more
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development...Read more
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program...Read more
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed...Read more
MeiraGTx to receive $200 million in upfront cash consideration MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to...Read more
Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas / Mar 13, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) is pleased to announce a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance...Read more
CHICAGO, March 12, 2025 (GLOBE NEWSWIRE) -- Cylinder, the leading virtual digestive health provider, today announced its partnership with Teladoc Health (NYSE: TDOC), the global leader in virtual care, to expand access to high-quality, personalized gastrointestinal care. Through this collaboration, Teladoc Health’s health plan and employer customers can easily provide members access to Cylinder's evidence-based digestive health platform,...Read more
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies, today announced entry into an agreement for Emergent’s strategic financial...Read more
Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388 Collaboration will complement Roche's portfolio in the field of cardiovascular, renal, and metabolic (CVRM) diseases Obesity is a heterogeneous disease with over 200 related comorbidities, including cardiovascular and metabolic diseases, and is expected to impact over 4 billion...Read more
HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the...Read more
CARLSBAD, Calif. & OSAKA, Japan / Mar 11, 2025 / Business Wire / Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening...Read more
Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories With this collaboration, Ainos takes a major step in its mission to digitize scent - expanding its expertise from healthcare applications to industrial automation. AI Nose, originally developed for volatile organic compound (VOC) detection in medical diagnostics, is now expanding to smart factories. By unlocking insights from invisible...Read more
Industry Leaders Partner to Advance Vision Testing and Digital Solutions to Expand Patient Access to Eye Care Globally ALISO VIEJO, Calif. / Mar 11, 2025 / Business Wire / Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR’s new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR’s innovative visual field platform and Topcon...Read more
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases INGELHEIM, Germany and PLEASANTON, Calif., March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine...Read more
MINNEAPOLIS, March 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet, an AI-powered Real World Data leader, has announced a collaboration with Datavant, a health data platform, to provide access to tokenized, purpose-built data for life sciences and medical research through Datavant’s health data ecosystem. Leveraging OneMedNet’s network of 31M patients, 121M+ clinical studies—EMR insights like images, ECGs, and notes—this collaboration enables life...Read more
SAN DIEGO / Mar 06, 2025 / Business Wire / Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering from end stage renal disease (ESRD). The...Read more
CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers’ Compensation claims Partnership expected to enable Lifeward to achieve greater growth and penetration into the Workers’ Compensation market MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel and GREEN BAY, Wis., March 06, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward”) a global leader in innovative medical...Read more
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular...Read more
NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare...Read more
Strategic initiative to address Ukraine’s urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its...Read more
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in...Read more
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla. / Mar 04, 2025 / Business Wire / Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K...Read more
First three consumer products expected to launch in Q3 2025, providing near-term revenue growth Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional...Read more
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection Princeton, New Jersey, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned...Read more
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical...Read more
SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology...Read more
LEXINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year global distribution and collaboration agreement (the “Agreement”) with the...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE